# A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.

Study · id `cardio:ct-nct03998319` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03998319](<https://clinicaltrials.gov/study/NCT03998319>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03998319

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 445 participants.

## Technical summary

Registry record NCT03998319. Randomized; quadruple masking; primary purpose other. Start 2021-10-14 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose other
- Phase: Phase 3
- Enrolled: 445 participants (planned count; ClinicalTrials.gov record NCT03998319, source copy `cardio:ctgov-nct03998319-2024-09-27`, retrieved 2026-10-26)
- Started: 2021-10-14 (actual) (ClinicalTrials.gov record NCT03998319, source copy `cardio:ctgov-nct03998319-2024-09-27`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT03998319, source copy `cardio:ctgov-nct03998319-2024-09-27`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT03998319, source copy `cardio:ctgov-nct03998319-2024-09-27`, retrieved 2026-10-26)
- Countries: Australia; New Zealand (ClinicalTrials.gov record NCT03998319, source copy `cardio:ctgov-nct03998319-2024-09-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03998319-2024-09-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.
- Acronym: RESTORE-MI
- Condition: STEMI
- Condition: Elevated IMR (&gt;32)
- Intervention (Drug): Tenecteplase (1/3 systemic weight based dose)
- Intervention (Other): Sterile water for injection (WFI)
- Lead sponsor: University of Sydney
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: University of Sydney (`cardio:org-university-of-sydney`)

## Provenance

Content hash: 8da30157beab1e0d23f988c2f5d803e3ac02c78887c3af015a16f28db91aa519
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
